Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06163430 | A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL) | PHASE1/PHASE2 | RECRUITING | 180 | — | — | Mar 1, 2024 | May 1, 2030 | Jan 11, 2026 | - | — |
| Name | Type | Description |
|---|---|---|
| TERN-701 | DRUG | TERN-701 orally QD |